Daratumumab: Difference between revisions
From IDWiki
(Created page with "* Anti-CD38 antibody used in the treatment of multiple myeloma * Risk of infections, including CMV Category:Medications Category:Hematology Category:Oncology") |
No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
+ | == Background == |
||
− | * Anti-CD38 antibody used in the treatment of [[multiple myeloma]] |
||
+ | * IgG1K human monoclonal antibody targetting CD38 |
||
⚫ | |||
+ | * Indications include [[multiple myeloma]] |
||
+ | |||
+ | == Adverse Effects == |
||
+ | * Adverse effects include [[hypertension]] (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis |
||
⚫ | |||
+ | |||
+ | == Further Reading == |
||
+ | |||
+ | * [https://www.cancercareontario.ca/en/system/files_force/daratumumab.pdf?download=1 Cancer Care Ontario drug monograph] |
||
[[Category:Medications]] |
[[Category:Medications]] |
Latest revision as of 11:03, 9 February 2023
Background
- IgG1K human monoclonal antibody targetting CD38
- Indications include multiple myeloma
Adverse Effects
- Adverse effects include hypertension (10%), edema, fatigue, cytopenias including anemia, liver enzyme abnormalities, infusion reactions (35% with first infusion), cytokine release syndrome, anaphylaxis, electrolyte abnormalities, headache (10%), insomnia, cough, dyspnea, rhinitis
- Risk of infections, including CMV, HSV, and possible hepatitis B